Uncategorized Archives - Page 236 of 248

TuesdayMay 30, 2017 4:36 pm

SinglePoint, Inc. (SING) Targeting Market Domination

Two significant acquisitions in the last three months is more than a pattern. It’s an out-right destination. This recent audio interview http://nnw.fm/8w4N9 with Greg Lambrecht, CEO of SinglePoint (OTC: SING), discusses some of the synergies and the immense opportunities that come with the company’s recent acquisition of 90% of Discount Indoor Garden Supply (“DIGS”) (www.DIGSHydro.com). These strategic accretive acquisitions position SinglePoint to become a dominant player in the California cannabis market while never actually touching the plant. In March, SinglePoint announced its acquisition of Orange County-based Convectium, which provides branding, packaging, equipment and a proprietary oil filling system ready to…

TuesdayMay 30, 2017 10:41 am

ChineseInvestors.com, Inc. (CIIX) Debuts “OptHemp” Premium Line and Readies its First U.S. Retail Store

ChineseInvestors.com’s (OTCQB: CIIX) first retail store is expected to open in June in San Gabriel, California. It will be among the first stores to sell “OptHemp,” a premium health product line launched by CIIX’s wholly owned subsidiary chinesehempoil.com, Inc. The “OptHemp” line will include OptHemp Ultra Premium Hemp Oil, the company’s first private label product. CIIX offers educational tools and consulting services for Chinese investors. Recently, it has been pursuing its niche in the expanding cannabis (CBD) market. The company’s goal is to become a leading Chinese publicly traded company in the nutritional industry. CIIX’s retail store in California will…

WednesdayMay 24, 2017 3:01 pm

India Globalization Capital, Inc. (NYSE: IGC) Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology. IGC is engaged in the development of cannabis-based therapies, which treat pain, terminal neurological and oncological diagnosis, PTSD, seizures, and other life altering issues. The company, based in Bethesda, Maryland, has a portfolio of patent filings for its phytocannabinoid-based treatments. In a news release, Ram Mukunda, CEO of IGC, welcomed Cheifetz to the company's advisory team, noting that he looks forward to Chiefetz's contributions as IGC develops unique cannabis combination therapies.…

WednesdayMay 24, 2017 9:00 am

Evolution of Marijuana Industry Creates Wealth of Opportunity for Companies with Foresight and Action

CannabisNewsWire Editorial Coverage: The marijuana industry continues to evolve at a breakneck pace in the United States, and an increasing number of businesses are finding their niche in this rampant market as it burns toward nationwide legalization. In the wake of this evolution, various new types of businesses are emerging to provide the consumer and commercial markets with products and services such as branding and packaging, smoke lounges, cultivation operations, grow equipment, pain management, payment solutions and numerous others. SinglePoint, Inc. (SING) (SING Profile), Medical Marijuana, Inc. (MJNA), Kush Bottles, Inc. (KSHB), Scott’s Miracle-Gro Co. (SMG) and Canopy Growth Corp.…

TuesdayMay 23, 2017 1:08 pm

ChineseInvestors.com (CIIX) Growing Rapidly in a Rapidly Growing Market

Savvy investors study multiple factors to identify potential stock winners. Stock screeners scan thousands of companies for insights and data to discern uncommon opportunities. The criteria utilized in a stock screening system is obviously influenced by an individual’s investment proclivities such as high yield, value, growth or price momentum, however, most stock screening systems are typically hybrids with blended criteria reflecting individual preferences and incorporating more than one investment style. P/E ratios, near zero beta, increased dividends, revenue growth and market growth are all employed to sift through over 100,000 public companies around the world and the nearly 6,000 U.S.…

MondayMay 22, 2017 9:19 am

India Globalization Capital, Inc. (NYSE: IGC) Developing Phytocannabinoid-Based Product Pipeline to Treat Two- and Four-Legged Alike

Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals. The company’s focus is on treating pain, post-traumatic stress disorder (PTSD), chronic and terminal neurological and oncological diagnoses, cachexia, and other life-altering medical conditions. IGC continues developing a portfolio of patent filings for phytocannabinoid-based treatments and has filed six patents to date. The company currently has three products in pre-clinical trials: IGC-501 for treatment of neuropathic pain in adult humans, IGC-502 for treatment of seizures in animals,…

ThursdayMay 18, 2017 11:49 am

India Globalization Capital, Inc. (NYSE: IGC) is Blazing a Trail with its Cannabis Plus Therapies

Slowly but surely cannabis is losing the stigma that has plagued it for close to one hundred years. Even some who frown on its use for recreational purposes are willing to consider that there may be therapeutic benefits in extracts of the cannabis sativa plant and so, increasingly, cannabinoids are being investigated to determine their effectiveness to treat a variety of debilitating medical conditions. Cannabinoid pharma is emerging as an entirely new industry segment in pharmaceuticals, and, as it does so, one innovative research company is blazing a trail in this new market by creating a niche of its own.…

WednesdayMay 17, 2017 9:00 am

Cannabis-Based Therapies with Potential to Dull the Pain of Opioid Abuse

CannabisNewsWire Editorial Coverage: America is in an opioid epidemic. On an average day, 91 Americans will die from an opioid-related overdose. That’s according to the CDC, which also reports that the number of prescription opioids sold in the U.S. has nearly quadrupled since 1999 despite no overall change in the amount of pain reported. The result is more than half a million deaths by opioid overdose from 2000 to 2015. These sobering figures reveal the desperate need for opioid substitutes, and cannabis-based therapies for pain treatment are emerging as viable alternatives. The potential rewards are significant for companies that can…

TuesdayMay 16, 2017 1:25 pm

SinglePoint (SING) Diversification Strategy Sets Stage for Big Rewards When Cannabis Industry Becomes Bankable

While some investors still view the marijuana market as a new industry, the mammoth potential of the cannabis industry — both in the United States and worldwide — cannot be discounted. While marijuana has not yet been legalized in the U.S. at the federal level, 29 states as well as the District of Columbia have, so far, passed laws or initiatives to legalize or regulate it, and the industry has been growing at an unexpectedly high rate. Some savvy companies are safeguarding against the risk of violating present federal laws by capitalizing on the growth of the cannabis industry in…

MondayMay 15, 2017 9:49 am

ChineseInvestors.com, Inc. (CIIX) Projected To Reach Revenue of $14.8 Million by FY2020 in Consilium Global Research Report

ChineseInvestors.com, Inc. (OTCQB: CIIX) is projected to reach revenues of $14.8 million by fiscal year 2020, according to a new research report by Consilium Global Research (http://nnw.fm/kKO7e). Per the report, the company did $930,000 in revenue for fiscal 2016 and is projected to grow at a compound annual growth rate (CAGR) of approximately 100% through 2020. The underlying market’s CAGR will expand at an 80% rate, the report said. Consilium sees CIIX as going through a huge transformation this year as it pursues a larger stake in the cannabis market. Headquartered in San Gabriel, California, CIIX offers a range of…